[1]唐琛 史宏志 韩红亚 刘晓丽 赵亦骢 王琛茜 张佳宜.应激性心肌病的研究进展[J].心血管病学进展,2024,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.005]
　TANG Chen,SHI Hongzhi,HAN Hongya,et al.Stress-Induced Cardiomyopathy[J].Advances in Cardiovascular Diseases,2024,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2024.07.005]
点击复制

应激性心肌病的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年7期
页码:
593
栏目:
综述
出版日期:
2024-07-25

文章信息/Info

Title:
Stress-Induced Cardiomyopathy
作者:
唐琛1 史宏志2 韩红亚3 刘晓丽3 赵亦骢1 王琛茜1 张佳宜1
(1.首都医科大学,北京 100069;2.解放军总医院第一医学中心普通外科医学部,北京100853;3.首都医科大学附属北京安贞医院老年心血管病中心,北京 100029)
Author(s):
TANG Chen1; SHI Hongzhi2; HAN Hongya3; LIU Xiaoli3; ZHAO Yicong1; WANG Chenxi1; ZHANG Jiayi1
Capital Medical UniversityBeijing 100069China; 2.Department of General Surgery,The First Medical Center of Chinese PLA General Hospital,Beijing 100853,China; 3.Geriatric Cardiovascular CenterBeijing Anzhen HospitalCapital Medical UniversityBeijing 100029China)
关键词:
应激性心肌病; 儿茶酚胺; 嗜铬细胞瘤; β肾上腺素能受体阻滞剂
Keywords:
Stress-induced cardiomyopathy;  Catecholamine;  Pheochromocytoma; -adrenergic receptor blocker
DOI:
10.16806/j.cnki.issn.1004-3934.2024.07.005
摘要:
应激性心肌病是以可逆性室壁运动异常为特征的一种心血管综合征，临床表现与急性冠状动脉综合征相似，但冠状动脉造影显示冠状动脉解剖正常。应激性心肌病的发病机制尚未完全明确，临床诊断不易，标准治疗药物存在争议，因并发症和复发风险导致预后不佳。现总结应激性心肌病的流行病学、发病机制、诊断和治疗方面的最新进展，以期为改善疾病的预后提供思路。
Abstract:
Stress-induced cardiomyopathy ,a cardiovascular syndrome characterized by reversible myocardial akinesia,mimics an acute coronary syndrome,but reveals normal coronary arteries. The underlying mechanism of stress-induced cardiomyopathy remains elusive,the diagnosis is often challenging and the pharmacotherapy is controversial. Due to fatal complications and high risk of recurrence,stress-induced cardiomyopathy has a poor prognosis. The article reviews the latest progress in the epidemiology ,pathogenesis,diagnosis and treatment of stress-induced cardiomyopathy,in order to provide ideas for improving the prognosis of the disease

参考文献/References:

[1].Mahajani V,Suratkal V. Broken Heart Syndrome[J].J Assoc Physicians India,2016,64(6):60-63.
[2].Lezzi P,Lupo R,Cimarelli N,et al. Clinical features of Takotsubo syndrome and its differential diagnostic criteria in clinical nursing practice:a review of the literature[J]. Curr Cardiol Rep,2023,25(8):841-850.
[3].Ghadri JR,Wittstein IS,Prasad A,et al. International Expert Consensus Document on Takotsubo Syndrome (Part I):Clinical Characteristics,Diagnostic Criteria,and Pathophysiology[J]. Eur Heart J,2018,39(22):2032-2046.
[4].Waqar A,Jain A,Joseph C,et al. Cardioprotective role of estrogen in Takotsubo cardiomyopathy[J]. Cureus ,2022,14(3):e22845.
[5].Bairashevskaia AV,Belogubova SY,Kondratiuk MR,et al. Update of Takotsubo cardiomyopathy:present experience and outlook for the future[J]. Int J Cardiol Heart Vasc,2022,39:100990.
[6].Swenson S,Bull J,Chen IB,et al. Takotsubo cardiomyopathy:a discussion and case study[J]. J Am Assoc Nurse Pract,2018,30(7):392-397.
[7].Esler M. Mental stress and human cardiovascular disease[J]. Neurosci Biobehav Rev,2017,74(Pt B):269-276.
[8].Sancassiani F,Carta MG,Montisci R,et al. Takotsubo syndrome is associated with mood disorders and antidepressants use,not with anxiety and impairment of quality of life due to the psychiatric disorder[J]. Clin Pract Epidemiol Ment Health,2018,14:26-32.
[9].Oliveri F,Goud HK,Mohammed L,et al. Role of depression and anxiety disorders in Takotsubo syndrome:the psychiatric side of broken heart[J].Cureus,2020,12(9):e10400.
[10].曾正陪. 嗜铬细胞瘤和副神经节瘤诊断治疗专家共识(2020版)[J]. 中华内分泌代谢杂志,2020,36(9):737-750.
[11].Szatko A,Glinicki P,Gietka-Czernel M. Pheochromocytoma/paraganglioma-associated cardiomyopathy[J]. Front Endocrinol (Lausanne),2023,14:1204851.
[12].Awadji FB,Sasmita BR,Huang B,et al. Takotsubo cardiomyopathy induced by pheochromocytoma:a case report[J]. Oxf Med Case Reports,2023,2023(2):omad011.
[13].Cornu E,Motiejunaite J,Belmihoub I,et al. Acute stress cardiomyopathy:heart of pheochromocytoma[J]. Ann Endocrinol (Paris),2021,82(3-4):201-205.
[14].Louis S,Selma H,Nicolas T. Pheochromocytoma-induced cardiogenic shock[J].Acta Chir Belg,2023,123(5):573-576.
[15].Campana N,Gioi A,Marchetti MF,et al. Catecholamine-induced Takotsubo syndrome:a case series[J]. Eur Heart J Case Rep,2023,7(7):ytad284.
[16].Kido K,Guglin M. Drug-induced Takotsubo cardiomyopathy[J]. J Cardiovasc Pharmacol Ther,2017,22(6):552-563.
[17].Moady G,Atar S. Stress-induced cardiomyopathy-considerations for diagnosis and management during the COVID-19 pandemic[J]. Medicina (Kaunas),2022,58(2):192.
[18].Land S,Niederer SA,Louch WE,et al. Computational modeling of Takotsubo cardiomyopathy:effect of spatially varying β-adrenergic stimulation in the rat left ventricle[J]. Am J Physiol Heart Circ Physiol,2014,307(10):H1487-H1496.
[19].Medina de Chazal H,del Buono MG,Keyser-Marcus L,et al. Stress cardiomyopathy diagnosis and treatment:JACC state-of-the-art review[J]. J Am Coll Cardiol,2018,72(16):1955-1971.
[20].Wang J,Hao D,Zeng L,et al. Neuropeptide Y mediates cardiac hypertrophy through microRNA-216b/FoxO4 signaling pathway[J]. Int J Med Sci,2021,18(1):18-28.
[21].Arai T,Kanazawa H,Kimura K,et al. Upregulation of neuropeptide Y in cardiac sympathetic nerves induces stress (Takotsubo) cardiomyopathy[J].Front Neurosci,2022,16:1013712.
[22].Ziaka M,Exadaktylos A. The heart is at risk: understanding stroke-heart-brain interactions with focus on neurogenic stress cardiomyopathy—A review[J].?J Stroke,2023,25(1):39-54.
[23].M?ller C,Stiermaier T,Meusel M,et al. Microcirculation in patients with Takotsubo syndrome-the prospective CIRCUS-TTS study [J]. J Clin Med,2021,10(10):2127.
[24].Topf A,Mirna M,Paar V,et al. Differential diagnosis between Takotsubo syndrome and acute coronary syndrome-a prospective analysis of novel cardiovascular biomarkers for a more selective triage[J]. J Clin Med,2022,11(11):2974.
[25].Santoro F,Mallardi A,Leopizzi A,et al. Stepwise approach for diagnosis and management of Takotsubo syndrome with cardiac imaging tools [J]. Heart Fail Rev,2022,27(2):545-558.
[26].Singh T,Khan H,Gamble DT,et al. Takotsubo syndrome:pathophysiology,emerging concepts,and clinical implications[J]. Circulation,2022,145(13):1002-1019.
[27].Santoro F,Sharkey S,Citro R,et al. Beta-blockers and renin-angiotensin system inhibitors for Takotsubo syndrome recurrence:a network meta-analysis[J]. Heart,2024,110(7):476-481.
[28].Aimo A,Pelliccia F,Panichella G,et al. Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity[J]. Int J Cardiol,2021,333:45-50.
[29].Isogai T,Matsui H,Tanaka H,et al. Early β-blocker use and in-hospital mortality in patients with Takotsubo cardiomyopathy[J]. Heart,2016,102(13):1029-1035.
[30].Papp Z,Agostoni P,Alvarez J,et al. Levosimendan efficacy and safety :20 years of SIMDAX in clinical use[J]. J Cardiovasc Pharmacol,2020,76(1):4-22.
[31].Zalewska-Adamiec M,Bachórzewska-Gajewska H,Dobrzycki S. The use of sacubitril/valsartan in Takotsubo syndrome with severe impairment of left ventricular systolic function[J]. Pol Arch Intern Med,2023,133(9):16545.
[32].El-Khodary NM,Ghoneim AI,El-Tayaar AA,et al. The impact of trimetazidine on cardiac fibrosis,inflammation,and function in ischemic cardiomyopathy patients[J]. Cardiovasc Drugs Ther,2023,37(5):955-964.
[33].Fan Q,Niu Z,Ma L. Meta-analysis of trimetazidine treatment for cardiomyopathy[J]. Biosci Rep,2018,38(3):BSR20171583.
[34].Templin C,Ghadri JR,Diekmann J,et al. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy[J]. N Engl J Med,2015,373(10):929-938.
[35].St?llberger C,Finsterer J,Schneider B. Left ventricular thrombi and embolic events in Takotsubo syndrome despite therapeutic anticoagulation[J]. Cardiology,2020,145(8):504-510.
[36].Santoro F,Mallardi A,Leopizzi A,et al. Current knowledge and future challenges in Takotsubo syndrome:part 2-treatment and prognosis[J]. J Clin Med,2021,10(3):468.
[37].Scally C,Rudd A,Mezincescu A,et al. Persistent long-term structural,functional,and metabolic changes after stress-induced (Takotsubo) cardiomyopathy[J]. Circulation,2018,137(10):1039-1048.
[38].Akashi YJ,Nef HM,Lyon AR. Epidemiology and pathophysiology of Takotsubo syndrome[J]. Nat Rev Cardiol,2015,12(7):387-397.
[39].Xu Z,Li Q,Liu R,et al. Very early recurrence of Takotsubo syndrome[J]. Ann Noninvasive Electrocardiol,2014,19(1):93-97.
[40].Cerrito M,Caragliano A,Zema D,et al. Very late recurrence of Takotsubo syndrome[J]. Ann Noninvasive Electrocardiol,2012,17(1):58-60.

相似文献/References:

[1]丁晓彤 张欣 左海奇 孙雨萌 贾赫 刘宏伟 孙鑫 孙延明 王岚峰 王姝.应激性心肌病诊治进展[J].心血管病学进展,2019,(5):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
　DING Xiaotong,ZHANG Xin,ZUO Haiqi,et al.Diagnosis and Treatment of Takotsubo Sydrome[J].Advances in Cardiovascular Diseases,2019,(7):778.[doi:10.16806/j.cnki.issn.1004-3934. 2019.05.028]
[2]王振伟 王涟 徐标.应激性心肌病患者临床特点及预后分析[J].心血管病学进展,2019,(5):831.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.041]
　WANG Zhenwei,WANG Lian,XU Biao.Clinical Features and Prognosis of Patients with Takotsubo Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(7):831.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.041]

更新日期/Last Update: 2024-08-09